Flash Therapeutics resumed its production and analytical activities on Monday March 23rd in order to ensure the follow-up of our clinical research work, as well as that of our partners and customers. As soon as the technical activities are completed, the concerned teams will return home and ensure traceability and follow-up remotely. All managers are committed to organizing the daily routine and logistics around on-site activities to ensure the safety of our employees present. Since the beginning of this health crisis, and in compliance with government regulations, all Flash Therapeutics’ employees who are able to continue their work remotely have been able to do so from home. All Flash Therapeutics’ employees are now connected from home. Should government measures change then we will keep you informed of our activity.
Using the LentiFlash® technology, Flash Therapeutics can recover a wide range of therapeutic fields
Non-integrating lentiviral particles called LentiFlash® for transient RNA delivery
Discover our own internal product candidates and collaborative programmes
We look forward to negotiate partnerships and licensingagreements with pharmaceutical or biotechnological companiesfor the utilization, further development and globalcommercialization of the proprietary LentiFlash® delivery system.Join us